LEXINGTON, Mass., May 15, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced ...
Apertura has licensed its novel TfR1 capsid (TfR1 CapX) to partners targeting CNS disorders TfR1 CapX enables broad brain distribution via intravenous dosing, meeting the urgent need for a ...
Voyager Therapeutics, Inc. announced the peer-reviewed publication of groundbreaking research showcasing the role of alkaline phosphatase (ALPL) in transporting a novel AAV capsid, VCAP-102, across ...
Over the last three decades, scientists have devised molecular shuttles that slip enzymes, antibodies, and other molecules into the central nervous system (CNS) by attaching them to the transferrin ...
It is far easier and safer to inject drugs into veins than directly into the brain, yet it is extremely difficult for systemically delivered drugs to cross the blood-brain barrier and achieve ...
Out of the many challenges scientists face in bringing genomic medicine to patients, delivery is near the top of the list. Due to these barriers in getting the genetic payload to the correct target ...
Adeno-associated viruses (AAV) have emerged as pivotal delivery vehicles for gene therapy due to their overall safety (less immunogenic), efficiency (broad tropism), and long-term gene expression.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback